Evidence map›Paper›PMID 32537180›Full record

ArticleNeuro-oncology practice2020

Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014.

Quinn T Ostrom, Gabrielle Truitt, Haley Gittleman, Daniel J Brat, Carol Kruchko, Reda Wilson, Jill S Barnholtz-Sloan

Open access · greenAbstract read
In one paragraph

Article in Neuro-oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Circadian GeneInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Quinn T OstromCentral Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.ORCID 0000-0003-3469-7558
Gabrielle TruittCentral Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
Haley GittlemanCentral Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.ORCID 0000-0002-6976-8777
Daniel J BratDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Carol KruchkoCentral Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
Reda WilsonDivision of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jill S Barnholtz-SloanCentral Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.ORCID 0000-0001-6190-9304
Central Brain Tumor Registry of the United States · USBaylor College of Medicine · USCenters for Disease Control and Prevention · USNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe majority of reported cancer survival statistics in the United States are generated using the National Cancer Institute's publicly available Surveillance, Epidemiology, and End Results (SEER) data, which prior to 2019 represented 28% of the US population (now 37%). In the case of rare cancers or special subpopulations, data sets based on a larger portion of the US population may contribute new insights into these low-incidence cancers. The purpose of this study is to characterize the histology-specific survival patterns for all primary malignant and nonmalignant primary brain tumors in the United States using the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR).

methodsSurvival data were obtained from the NPCR (includes data from 39 state cancer registries, representing 81% of the US population). Relative survival rates (RS) with 95% CI were generated using SEER*Stat 8.3.5 from 2004 to 2014 by behavior, histology, sex, race/ethnicity, and age at diagnosis.

resultsOverall, there were 488 314 cases from 2004 to 2014. Overall 5-year RS was 69.8% (95% CI = 69.6%-69.9%). Five-year RS was 35.9% (95% CI = 35.6%-36.1%) for malignant and 90.2% (95% CI = 90.1%-90.4%) for nonmalignant tumors. Pilocytic astrocytoma had the longest 5-year RS (94.2%, 95% CI = 93.6%-94.6%) of all glioma subtypes, whereas glioblastoma had the shortest 5-year RS (6.1%, 95% CI = 6.0%-6.3%). Nonmalignant nerve sheath tumors had the longest 5-year RS (99.3%, 95% CI = 99.1%-99.4%). Younger age and female sex were associated with increased survival for many histologies.

conclusionsSurvival after diagnosis with primary brain tumor varies by behavior, histology, and age. Using such a database that includes more than 80% of the US population may represent national survival patterns.

Indexed as

brain and CNS tumorsNational Program of Cancer Registries (NPCR)relative survivalUnited StatesUnited States Cancer Statistics (USCS)

Identifiers

PMID32537180
PMCPMC7274192
OpenAlexW2994689971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.